Government of Canada provides support for ParticipACTION to promote active lifestyles Français
ParticipACTION engages Canadians online and in their communities through its Community Challenge, making it easier for everyone to be active, especially groups facing barriers to physical activity.
Staying active improves both physical and mental health and reduces the risk of chronic disease. This investment underscores our commitment to healthier, more active communities across Canada.
Quotes
"Across Canada, physical inactivity and sedentary behaviour continue to be a challenge. Being active is key for preventing chronic disease and improving overall health and well-being. This is why we partner with organizations like ParticipACTION to promote healthier and active lifestyles nationwide."
The Honourable Marjorie Michel
Minister of Health
"Moving your body should be simple, but for too many people, it's still out of reach. Let's Get Moving is about making physical activity more accessible so more Canadians can move more, feel better and live healthier lives."
The Honourable Adam van Koeverden
Secretary of State (Sport)
"We thank the Government of Canada for its continued commitment to supporting ParticipACTION's important work. Physical activity isn't just good for us—it's essential for a longer, healthier, and more fulfilling life. It strengthens our bodies, minds, and communities. Now is the time to make physical activity a national priority and ensure that every person in Canada has the opportunity to be active every day."
Elio Antunes
President and CEO of ParticipACTION
Quick Facts
ParticipACTION is a Canadian non-profit charitable organization that has been encouraging Canadians to get healthy by making physical activity an integral part of their everyday life since 1971.
Since 2018, the Let's Get Moving initiative has achieved results across its program of activities, including public education, research and community-based physical activity challenges. Last year alone, Let's Get Moving reached 568,000 participants through the Community Challenge. With this funding, this initiative is expected to deliver positive outcomes that will benefit as many people in Canada as possible, including priority populations.
Physical inactivity and sedentary behaviour levels remain high with only 49.2% of adults and 43.9% of children and youth meeting physical activity recommendations in Canada.
SOURCE Public Health Agency of Canada (PHAC)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
4 hours ago
- Cision Canada
Public advisory - Unlicensed Mitolux UV sunlamps for Vitamin D may pose health risks Français
, /CNW/ - Summary Product: Unlicensed ultraviolet (UV) sunlamps Issue: Health products – Unauthorized product; Product safety What to do: Do not use unlicensed Mitolux UV sunlamps. Consult a health care professional if you have used any of these sunlamps and have concerns about your health. Check whether medical devices have been licensed for sale by searching Health Canada's Medical Devices Active Licence Listing. Report any health product-related side effects or complaints to Health Canada. Affected products Issue Health Canada is warning consumers that unlicensed ultraviolet (UV) sunlamps sold by Mitolux may pose health risks due to excessive and unsafe ultraviolet B (UVB) radiation levels. The devices are marketed to be a reliable source of natural Vitamin D. Too much exposure to UVB radiation from using Mitolux UV sunlamps can cause: skin reactions and burns eye damage premature skin aging skin cancer with repeated exposure It is illegal to advertise for sale, import for sale, or sell medical devices in Canada without appropriate licensing under the Medical Devices Regulations. Health Canada is asking companies that sell Mitolux UV sunlamps to immediately stop selling them. Should additional safety concerns be identified, Health Canada will take appropriate action to protect public health and safety, including communicating updates, if needed. What you should do
Cision Canada
6 hours ago
- Cision Canada
BTL Expands EMFACE® Indications with New FDA Clearance for TMJ Dysfunction
BOSTON, Aug. 13, 2025 /CNW/ -- BTL Industries, a global leader in medical and wellness technologies, has expanded the FDA-cleared applications of its EMFACE® platform with a new indication for the treatment of temporomandibular joint (TMJ) dysfunction. EMFACE® is now cleared by the FDA for the relief of symptoms associated with muscle spasm, treatment of TMJ dysfunction and associated pain, muscle re-education, increased local blood flow, and the maintenance or improvement of mandibular range of motion. Developed through years of research and engineering, EMFACE combines synchronized radiofrequency and HIFES® technology for facial muscle stimulation, delivering relief without surgery, injections, or medication. "EMFACE is an established technology platform with multiple FDA-cleared uses," said David Chmel, CEO of BTL Industries. "This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients." "TMJ dysfunction impacts more than the jaw — it affects quality of life," said Shireen Dhanani, DMD, Leesburg, FL. "With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care." BTL continues to redefine what's possible in facial care and wellness, bringing science-backed technologies like EMFACE into new areas of medicine to improve lives and advance patient care worldwide. For more information about EMFACE, visit www. About BTL Industries Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. Operating in over 90 countries, BTL holds more than 200 patents and employs over 500 R&D engineers dedicated to advancing medical treatments through technology and science. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.
The Market Online
6 hours ago
- The Market Online
Tilray expands access to medical cannabis extracts in Italy
Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, an Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries Tilray stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021 Tilray Medical, a division of cannabis powerhouse Tilray Brands (TSX:TLRY), has partnered with Molteni, a top Italian pharmaceutical firm focused on pain therapies and substance dependence, to broaden the availability of its cannabis extracts across Italy. This content has been prepared as part of a partnership with Tilray Brands Inc., and is intended for informational purposes only. Under the partnership, Tilray Medical subsidiary, FL Group, will provide medical cannabis education throughout Molteni's network of pharmaceutical, scientific and medical professionals in Italy. Founded in 1892 and headquartered in Florence, Molteni maintains operations in more than 40 countries and benefits from in-house manufacturing, research and development, regulatory, supply chain and commercial capabilities, opening the door for future partnerships with Tilray down the line. The new partnership complements Tilray's existing operations in Italy, in addition to presences in Germany, Portugal, Poland and the United Kingdom, with European cannabis revenue growing by 112 per cent in fiscal 2025. Leadership insights 'This partnership reflects our commitment to advancing patient care through strategic collaboration,' Rajnish Ohri, Tilray Brands' Managing Director, International, said in Wednesday's news release. 'By combining FL Group's regulatory and distribution capabilities with Molteni's scientific leadership, we are not only expanding access to high-quality, EU-GMP certified cannabis therapies for patients across Italy but also prioritizing medical cannabis education for pain therapies. Through Molteni's extensive network of healthcare professionals, we aim to empower practitioners with the knowledge and resources needed to support patients seeking effective pain management solutions.' About Tilray Brands Tilray Brands is a cannabis, beverage, wellness and entertainment company supporting more than 40 brands in more than 20 countries. Tilray stock (TSX:TLRY) las traded at C$1.32. The cannabis stock has given back 48.03 per cent year-over-year and 93.28 per cent since May 2021. Join the discussion: Find out what everybody's saying about this Canadian cannabis stock on the Tilray Brands Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
